{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:05:48Z","timestamp":1790910348535,"version":"4.1.0"},"reference-count":135,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cancer patients have varying incidence, depth and duration of thrombocytopenia. The mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is the use of platelet transfusions. While prophylactic platelet transfusions reduce the bleeding rate, multiple unmet needs remain, such as high residual rates of bleeding, and anticancer treatment dose reductions\/delays. Accordingly, the following promising results in other settings, antifibrinolytic drugs have been evaluated for prevention and treatment of bleeding in patients with hematological malignancies and solid tumors. In addition, Thrombopoeitin receptor agonists have been studied for two major implications in cancer: treatment of severe thrombocytopenia associated with myelodysplastic syndrome and acute myeloid leukemia; primary and secondary prevention of CIT in solid tumors in order to maintain dose density and intensity of anti-cancer treatment. Furthermore, thrombocytopenic cancer patients are often prescribed antithrombotic medication for indications arising prior or post cancer diagnosis. Balancing the bleeding and thrombotic risks in such patients represents a unique clinical challenge. This review focuses upon non-transfusion-based approaches to managing thrombocytopenia and the associated bleeding risk in cancer, and also addresses the management of antithrombotic therapy in thrombocytopenic cancer patients.<\/jats:p>","DOI":"10.3390\/jcm10061169","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:38:22Z","timestamp":1615441102000},"page":"1169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Challenges and Advances in Managing Thrombocytopenic Cancer Patients"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"first","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 4941492, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6229 ER Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Hofstetter","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 4941492, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Spectre","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 4941492, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"Liebman","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1182\/blood.V64.5.1036.1036","article-title":"Busulfan-induced chronic bone marrow failure: Changes in cortical bone, marrow stromal cells, and adherent cell colonies","volume":"64","author":"McManus","year":"1984","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MD.0b013e318210e685","article-title":"High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases","volume":"90","author":"Dezern","year":"2011","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"172655","DOI":"10.1016\/j.ejphar.2019.172655","article-title":"Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy","volume":"862","author":"Suvarna","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2012.02.013","article-title":"Cisplatin induces platelet apoptosis through the ERK signaling pathway","volume":"130","author":"Zhang","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14225","article-title":"Acquired platelet antagonism: Off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors","volume":"16","author":"Tullemans","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/0008-5472.CAN-06-4303","article-title":"Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor","volume":"67","author":"Zeuner","year":"2007","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor\u2014Induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.20516","article-title":"Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin","volume":"81","author":"Curtis","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2257.2000.00305.x","article-title":"Autoimmune thrombocytopenia: A complication of fludarabine therapy in lymphoproliferative disorders","volume":"22","author":"Leach","year":"2000","journal-title":"Clin. Lab. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Thomas, M., and Scully, M. (2021). How I Treat Microangiopathic Hemolytic Anemia in Patients with Cancer. Blood.","DOI":"10.1182\/blood.2019003810"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1172\/JCI75247","article-title":"Proteasome function is required for platelet production","volume":"124","author":"Shi","year":"2014","journal-title":"J. Clin. Invest."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Beksac","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2014.118075","article-title":"Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: Recurrent event analysis","volume":"100","author":"Stanworth","year":"2015","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: An open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2017-01-757930","article-title":"Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial","volume":"130","author":"Uhl","year":"2017","journal-title":"Blood"},{"key":"ref_25","first-page":"1530","article-title":"The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia","volume":"91","author":"Webert","year":"2006","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.12928","article-title":"Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies-The ATHENA study","volume":"166","author":"Estcourt","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jth.14465","article-title":"Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion","volume":"17","author":"Henskens","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.16291","article-title":"The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: A cohort study","volume":"189","author":"Ypma","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/trf.14316","article-title":"How do I \u2026 manage the platelet transfusion\u2013refractory patient?","volume":"57","author":"Juskewitch","year":"2017","journal-title":"Transfusion"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1634\/theoncologist.9-5-561","article-title":"Management of bleeding in patients with advanced cancer","volume":"9","author":"Pereira","year":"2004","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ejh.13348","article-title":"The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients","volume":"104","author":"Cai","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): An international randomised, double-blind, placebo-controlled trial","volume":"395","author":"Roberts","year":"2020","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1160\/TH15-09-0740","article-title":"Supportive management strategies for disseminated intravascular coagulation: An international consensus","volume":"115","author":"Squizzato","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2017-10-804096","article-title":"How I treat disseminated intravascular coagulation","volume":"131","author":"Levi","year":"2018","journal-title":"Blood"},{"key":"ref_36","first-page":"637","article-title":"The role of antifibrinolytic agents in gynecologic cancer surgery","volume":"27","author":"Celebi","year":"2006","journal-title":"Saudi Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/02688697.2020.1717442","article-title":"Safety and efficacy of tranexamic acid in spinal canal tumors: A retrospective cohort study","volume":"34","author":"Zhang","year":"2020","journal-title":"Br. J. Neurosurg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4103\/0259-1162.161806","article-title":"Does the preoperative administration of tranexamic acid reduce perioperative blood loss and transfusion requirements after head neck cancer surgery? A randomized, controlled trial","volume":"9","author":"Das","year":"2015","journal-title":"Anesth. Essays Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.sla.0000197561.70972.73","article-title":"Perioperative parenteral tranexamic acid in liver tumor resection: A prospective randomized trial toward a \u201cblood transfusion\u201d-free hepatectomy","volume":"243","author":"Wu","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"d5701","DOI":"10.1136\/bmj.d5701","article-title":"Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: Double blind, randomised, placebo controlled trial","volume":"343","author":"Crescenti","year":"2011","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/aogs.12333","article-title":"Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: Double-blind placebo-controlled randomized multicenter study","volume":"93","author":"Lundin","year":"2014","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00000542-200302000-00011","article-title":"Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery","volume":"98","author":"Amar","year":"2003","journal-title":"Anesthesiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neuchi.2019.05.003","article-title":"Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid","volume":"65","author":"Damade","year":"2019","journal-title":"Neurochirurgie."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/1658-354X.146304","article-title":"Effect of low dose tranexamic acid on intra-operative blood loss in neurosurgical patients","volume":"9","author":"Vel","year":"2015","journal-title":"Saudi J. Anaesth."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0019-5049.174798","article-title":"Does tranexamic acid reduce blood loss during head and neck cancer surgery?","volume":"60","author":"Kulkarni","year":"2016","journal-title":"Indian J. Anaesth."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1378\/chest.100.3.847","article-title":"Tranexamic acid treatment of hemothorax in two patients with malignant mesothelioma","volume":"100","author":"Koolen","year":"1991","journal-title":"Chest"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/pgmj.69.807.80-a","article-title":"Antifibrinolytic therapy for haemoptysis related to bronchial carcinoma","volume":"69","author":"Kaufman","year":"1993","journal-title":"Postgrad. Med. J."},{"key":"ref_48","first-page":"e428","article-title":"Tranexamic Acid to Treat Life-threatening Hemorrhage in Prostate Cancer Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis","volume":"7","author":"Brose","year":"2015","journal-title":"Cureus"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0885-3924(96)00202-3","article-title":"Fibrinolytic inhibitors for cancer-associated bleeding problems","volume":"13","author":"Dean","year":"1997","journal-title":"J. Pain Symptom Manag."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.1980.03300270023023","article-title":"Aminocaproic Acid: Use in Control of Hemorrhage in Patients With Amegakaryocytic Thrombocytopenia","volume":"243","author":"Gardner","year":"1980","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1600-0609.1985.tb02818.x","article-title":"Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients","volume":"35","author":"Garewal","year":"1985","journal-title":"Scand. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0609.1998.tb01046.x","article-title":"Low dose bolus aminocaproic acid: An alternative to platelet transfusion in thrombocytopenia?","volume":"60","author":"Chakrabarti","year":"1998","journal-title":"Eur. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.21958","article-title":"Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage","volume":"107","author":"Kalmadi","year":"2006","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hon.867","article-title":"Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: A retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients","volume":"26","author":"Wassenaar","year":"2008","journal-title":"Hematol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cornelissen, L.L., Caram-Deelder, C., Meier, R.T., Zwaginga, J.J., and Evers, D. (2020). Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey. Eur. J. Haematol.","DOI":"10.1111\/ejh.13555"},{"key":"ref_56","first-page":"202a","article-title":"Antifibrinolytic therapy for bleeding control during remission induction for acute leukemia","volume":"62","author":"Gallardo","year":"1983","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/cncr.28253","article-title":"Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies","volume":"119","author":"Antun","year":"2013","journal-title":"Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hon.2189","article-title":"Aminocaproic acid use in hospitalized patients with hematological malignancy: A case series","volume":"34","author":"Marshall","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1080\/10428194.2018.1434882","article-title":"Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies","volume":"59","author":"Juhl","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","unstructured":"(2021, January 24). NCT02074436 Prevention of Bleeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02074436."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199509059668","article-title":"A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia","volume":"19","author":"Shpilberg","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","article-title":"Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia","volume":"2","author":"Avvisati","year":"1989","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1537-2995.1991.31491213301.x","article-title":"Lack of efficacy of tranexamic acid in thrombocytopenic bleeding","volume":"31","author":"Fricke","year":"1991","journal-title":"Transfusion"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0609.1990.tb00423.x","article-title":"Tranexamic acid therapy in acute myeloid leukemia: Possible reduction of platelet transfusions","volume":"45","author":"Douer","year":"1990","journal-title":"Eur. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ajh.20958","article-title":"Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Mori","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_66","first-page":"CD009733","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders","volume":"3","author":"Estcourt","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tmrv.2017.03.002","article-title":"The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis","volume":"31","author":"Montroy","year":"2017","journal-title":"Transfus. Med. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-138920","article-title":"Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial","volume":"136","author":"Gernsheimer","year":"2020","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s13063-019-3663-2","article-title":"The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): Safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: Study protocol for a double-blind randomised controlled tr","volume":"20","author":"Estcourt","year":"2019","journal-title":"Trials"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: Efficacy review and update on drug safety","volume":"9","author":"Bastida","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: Ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13684730050515912","article-title":"Megakaryocyte growth and development factor (MGDF): An Mpl ligand and cytokine that regulates thrombopoiesis","volume":"6","author":"Foote","year":"2000","journal-title":"Cytokines Cell. Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Vadhan-Raj, S. (2009). Management of Chemotherapy-Induced Thrombocytopenia: Current Status of Thrombopoietic Agents. Semin. Hematol., 46.","DOI":"10.1053\/j.seminhematol.2008.12.007"},{"key":"ref_74","unstructured":"(2018). Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China. Zhonghua Zhong Liu Za Zhi, 40, 714\u2013720."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3324\/haematol.2020.249995","article-title":"Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome","volume":"105","author":"Vicente","year":"2020","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","article-title":"Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: A multicentre, randomised, placebo-controlled, double-blind, phase 1\/2 trial","volume":"2","author":"Platzbecker","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(18)30231-X","article-title":"Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: A randomised, double-blind, phase 2 study","volume":"6","author":"Frey","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: Results of a phase 1\/2 multicenter trial","volume":"135","author":"Chevret","year":"2020","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2016.01.018","article-title":"Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Tanaka","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41409-020-0975-5","article-title":"Therapy of posttransplant poor graft function with eltrombopag","volume":"56","author":"Halahleh","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41409-019-0442-3","article-title":"Eltrombopag for post-transplant cytopenias due to poor graft function","volume":"54","author":"Marotta","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1359-6349(09)71900-7","article-title":"9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: Results from an open-label dose- and schedule-finding study","volume":"7","author":"Fanale","year":"2009","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.V116.21.1544.1544","article-title":"Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I\/II Study","volume":"116","author":"Hagemeister","year":"2010","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Zhang, X., Chuai, Y., Nie, W., Wang, A., and Dai, G. (2017). Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst. Rev., 2017.","DOI":"10.1002\/14651858.CD012035.pub2"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Al-Samkari, H., Parnes, A.D., Goodarzi, K., Weitzman, J.I., Connors, J.M., and Kuter, D.J. (2020). A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica.","DOI":"10.1182\/blood-2019-123864"},{"key":"ref_90","first-page":"e1799","article-title":"Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial","volume":"93","author":"Devos","year":"2019","journal-title":"Neurology"},{"key":"ref_91","unstructured":"(2021, January 29). Sobi Announces Topline Phase 3 Data of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia | Sobi. Available online: https:\/\/www.sobi.com\/en\/press-releases\/sobi-announces-topline-phase-3-data-avatrombopag-treatment-chemotherapy-induced."},{"key":"ref_92","unstructured":"(2021, January 30). Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03471078."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"103","author":"Marshall","year":"2018","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-013-2074-2","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1002\/ajh.25022","article-title":"A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia","volume":"93","author":"Miao","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1359-6349(09)71939-1","article-title":"9248 Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"7","author":"Natale","year":"2009","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: A randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and Venous Thromboembolic Disease: A Review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of Arterial Thromboembolism in Patients With Cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2018","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"Khanal","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.069559","article-title":"Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients","volume":"98","author":"Labrador","year":"2013","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","article-title":"The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: Implications for VTE prevention","volume":"112","author":"Gerber","year":"2008","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ahj.2010.11.001","article-title":"Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI)","volume":"161","author":"Hakim","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1634\/theoncologist.2016-0110","article-title":"Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction","volume":"22","author":"Feher","year":"2017","journal-title":"Oncologist"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clml.2017.09.008","article-title":"The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient Sample","volume":"18","author":"Kim","year":"2018","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.108.827162","article-title":"Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice","volume":"119","author":"Wang","year":"2009","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","article-title":"Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps","volume":"132","author":"Leader","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","article-title":"Management and outcomes of patients with atrial fibrillation and a history of cancer: The ORBIT-AF registry","volume":"3","author":"Melloni","year":"2017","journal-title":"Eur. Hear. J. Qual. Care Clin. Outcomes"},{"key":"ref_112","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: A retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/bloodadvances.2017006130","article-title":"Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation","volume":"1","author":"Li","year":"2017","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia","volume":"122","author":"Iliescu","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2020.07.021","article-title":"Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia","volume":"195","author":"Lecumberri","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow, B.T., Lee, A., Khorana, A.A., Zwicker, J.I., Noble, S., Ay, C., and Carrier, M. (2018). Management of cancer-associated thrombosis in patients with thrombocytopenia: Guidance from the SSC of the ISTH. J. Thromb. Haemost. JTH.","DOI":"10.1016\/j.thromres.2018.02.054"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11239-017-1539-4","article-title":"Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes","volume":"44","author":"Walter","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Houghton, D.E., Key, N.S., Zakai, N.A., Laux, J.P., Shea, T.C., and Moll, S. (2017). Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: A retrospective cohort. Leuk. Lymphoma, 1\u20139.","DOI":"10.1080\/10428194.2017.1306644"},{"key":"ref_125","first-page":"PB0909","article-title":"Anticoagulation management and outcomes in thrombocytopenic cancer patients with atrial fibrillation","volume":"3","author":"Livneh","year":"2019","journal-title":"Res Pr. Thromb Haemost"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11239-019-01807-y","article-title":"The efficacy and safety of a catheter removal only strategy for the treatment of PICC line thrombosis versus standard of care anticoagulation: A retrospective review","volume":"47","author":"Shatzel","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3747\/co.22.2587","article-title":"Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: Treatment","volume":"22","author":"Easaw","year":"2015","journal-title":"Curr. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11239-018-1711-5","article-title":"Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen","volume":"46","author":"Htun","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow, B.R., Lee, A.Y., Khorana, A.A., Zwicker, J.I., Simon, N., Cihan, A., and Marc, C. (2018). Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res. Pract. Thromb. Haemost.","DOI":"10.1016\/j.thromres.2018.02.054"},{"key":"ref_131","first-page":"6291","article-title":"Intracranial Hemorrhage with Direct Oral Anticoagulants in Patients with Brain Metastases [abstract]","volume":"4","author":"Leader","year":"2020","journal-title":"Res. Pr. Thromb. Haemost."},{"key":"ref_132","unstructured":"Leader, A., Spectre, G., ten Cate, H., Falanga, A., and for the MATTER investigators (2019, January 6\u201310). Prospective Cohort Study on Management and Outcomes in Thrombocytopenic Patients Receiving Antithrombotic Therapy. Proceedings of the 27th International Society of Thrombosis and Haemostasis (ISTH) Congress and 65rd Annual Scientific and Standardization Committee (SSC) Meeting, Melbourne, Australia."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ccd.26375","article-title":"SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiolog\u0131a Interve","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0038-1676520","article-title":"Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment","volume":"119","author":"Leader","year":"2019","journal-title":"Thromb. Haemost."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/6\/1169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:56Z","timestamp":1760160836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/6\/1169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":135,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["jcm10061169"],"URL":"https:\/\/doi.org\/10.3390\/jcm10061169","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}